REG - IXICO plc - Contract Win

IXICOAnnouncement

Tue 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250812:nRSL8557Ua&default-theme=true

RNS Number : 8557U  IXICO plc  12 August 2025

IXICO plc

("IXICO", the "Company" or the "Group")

 

Global clinical trial contract wins in Alzheimer's Disease

and Friedreich's Ataxia

 

 

12 August 2025 IXICO plc (AIM: IXI) - London, UK. IXICO, a global leader in
neuroscience imaging and biomarker analytics, using its AI-driven platform to
help advance drug development in neurological disorders, today announced it
has signed two separate new commercial contracts to provide neuroimaging
services across different core therapeutic indications. The combined value of
the new contracts is circa £1.3 million.

 

Under the first contract IXICO will provide trial management and imaging
analysis for a Phase 1 Alzheimer's Disease (AD) clinical trial by a major
pharmaceutical company. The contract scope covers a collaboration for
approximately three and a half years.

 

The second contract with a US-based biotech sees IXICO facilitating high
quality imaging data collection for a Phase 1b trial to aid surgical planning
in Friedrich's Ataxia (FA), a progressive inherited neurodegenerative disorder
that effects the nervous system and heart.  The contract scope covers a
collaboration for six years.

 

This positive commercial momentum continues IXICO's successful execution of
its 'Innovate, Lead, Scale' strategy to drive global expansion and growth.

 

Bram Goorden, CEO of IXICO, commented: "The contract wins underline the
innovative, adaptable and agile nature of the IXICO platform and our teams as
irrefutable thought leaders in the neurodegenerative disease space. The two
deals hit different key elements of our strategy, respectively supporting
Alzheimer's as a core indication, and; maintaining our leadership position in
the rare CNS disease space."

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulation
(EU) No. 596/2014 as amended by The Market Abuse (Amendment) (EU Exit)
Regulations 2019. Upon the publication of this announcement via the Regulatory
Information Service, this inside information is now considered to be in the
public domain.

Ends

 

For further information please contact:

 

 IXICO plc                                   +44 (0) 20 3763 7499
 Grant Nash, Chief Financial Officer

 James Chandler, Chief Business Officer

 Cavendish Capital Markets Limited           +44 (0) 20 7220 0500

 (Nominated Adviser and Sole Broker)
 Giles Balleny (Corporate Finance)

 Nigel Birks (Healthcare Specialist Sales)

 Harriet Ward (Corporate Broking)

 Michael F Johnson (Sales)

 

 

About IXICO www.IXICO.com (http://www.IXICO.com)

IXICO is a global leader in neuroscience imaging and biomarker analytics,
using its proprietary AI-driven platform to help advance the treatment of
neurological disorders and reduce the uncertainties associated with drug
discovery, development and monitoring.   As a key part of the global
neurological disease research community, the Company has built a global
reputation and 20-year track record as an end-to-end Imaging Contract Research
Organisation (iCRO) working with leading pharma companies, innovative
biotech's, disease consortia and non-profit organisations. IXICO has supported
hundreds of neurological clinical trials, analysed hundreds of thousands scans
and built an expansive network of expert imaging centres around the world.

 

The IXICO Platform is tailor-made for neurological disease, reliably
processing data from global trials, precisely measuring key imaging biomarkers
associated with the identification, progression and treatment of diseases such
as Alzheimer's, Huntington's and Parkinson's.  Image data is interrogated by
the Platform and IXICO's expert scientists translating complex data into
clinically meaningful while minimizing data variability and increasing
reproducibility.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTPKDBBQBKDNFD